

BELLICUM PHARMACEUTICALS, INC  
Form SC 13D  
December 24, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**SCHEDULE 13D**

**Under the Securities Exchange Act of 1934**

(Amendment No. )\*

**Bellicum Pharmaceuticals, Inc.**

(Name of Issuer)

Common Stock, Par Value \$0.01 Per Share

(Title of Class of Securities)

079481107  
(CUSIP number)

Alexandra A. Toohey

Chief Financial Officer

Baker Bros. Advisors LP

667 Madison Avenue, 21<sup>st</sup> Floor

New York, NY 10065

(212) 339-5690

(Name, address and telephone number of person authorized to receive notices and communications)

Not Applicable

(Date of event which requires filing of this statement)

Edgar Filing: BELLICUM PHARMACEUTICALS, INC - Form SC 13D

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. x

(Continued on the following pages)

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 079481107 Page 2 of 14 Pages

NAMES OF REPORTING PERSONS

1.

Baker Bros. Advisors LP

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

2.

(a) ..

(b) ..

SEC USE ONLY

3.

SOURCE OF FUNDS\*

4.

OO

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

5.

..

CITIZENSHIP OR PLACE OF ORGANIZATION

6.

Delaware

NUMBER OF  
SHARES                      SOLE VOTING POWER 4,865,647  
BENEFICIALLY 7.  
OWNED BY  
EACH

REPORTING PERSON WITH

8. SHARED VOTING POWER: 0

9. SOLE DISPOSITIVE POWER: 4,865,647

10. SHARED DISPOSITIVE POWER: 0

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 4,865,647

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

..

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

18.4% (1)

14. TYPE OF REPORTING PERSON (See Instructions)

IA, PN

(1) Based on 26,501,110 shares of common stock outstanding as of October 30, 2015, as reported in the Issuer's Form 10-Q filed with the SEC on November 9, 2015.

CUSIP No. 079481107 Page 3 of 14 Pages

NAMES OF REPORTING PERSONS

1.

Baker Bros. Advisors (GP) LLC

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

2.

(a) ..

(b) ..

SEC USE ONLY

3.

SOURCE OF FUNDS\*

4.

OO

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

5.

..

CITIZENSHIP OR PLACE OF ORGANIZATION

6.

Delaware

NUMBER OF  
SHARES                      SOLE VOTING POWER 4,865,647  
BENEFICIALLY 7.  
OWNED BY  
EACH

REPORTING PERSON WITH 8. SHARED VOTING POWER: 0

9. SOLE DISPOSITIVE POWER: 4,865,647

10. SHARED DISPOSITIVE POWER: 0

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 4,865,647

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

..

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

18.4% (1)

14. TYPE OF REPORTING PERSON (See Instructions)

HC, OO

(1) Based on 26,501,110 shares of common stock outstanding as of October 30, 2015, as reported in the Issuer's Form 10-Q filed with the SEC on November 9, 2015.

CUSIP No. 079481107 Page 4 of 14 Pages

NAMES OF REPORTING PERSONS

1.

Julian C. Baker

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

2.

(a) ..

(b) ..

SEC USE ONLY

3.

SOURCE OF FUNDS\*

4.

OO

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

5.

..

CITIZENSHIP OR PLACE OF ORGANIZATION

6.

United States

NUMBER OF SHARES

BENEFICIALLY OWNED BY EACH  
7. SOLE VOTING POWER: 4,865,647

REPORTING PERSON WITH 8. SHARED VOTING POWER: 0

9. SOLE DISPOSITIVE POWER: 4,865,647

10. SHARED DISPOSITIVE POWER: 0

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 4,865,647

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

..

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

18.4% (1)

14. TYPE OF REPORTING PERSON (See Instructions)

IN, HC

(1) Based on 26,501,110 shares of common stock outstanding as of October 30, 2015, as reported in the Issuer's Form 10-Q filed with the SEC on November 9, 2015.



CUSIP No 079481107 Page 5 of 14 Pages

NAMES OF REPORTING PERSONS

1.

Felix J. Baker

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

2.

(a) ..

(b) ..

SEC USE ONLY

3.

SOURCE OF FUNDS (See Instructions)

4.

OO

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

5.

..

CITIZENSHIP OR PLACE OF ORGANIZATION

6.

United States

NUMBER OF SHARES

BENEFICIALLY OWNED BY EACH  
7. SOLE VOTING POWER: 4,865,647

REPORTING PERSON WITH 8. SHARED VOTING POWER: 0

9. SOLE DISPOSITIVE POWER: 4,865,647

10. SHARED DISPOSITIVE POWER: 0

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 4,865,647

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

..

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

18.4% (1)

14. TYPE OF REPORTING PERSON (See Instructions)

IN, HC

(1) Based on 26,501,110 shares of common stock outstanding as of October 30, 2015, as reported in the Issuer's Form 10-Q filed with the SEC on November 9, 2015.

**Schedule 13D**

The class of equity security to which this statement on Schedule 13D relates is the common stock, par value \$0.01 per share (the “Common Stock”) of Bellicum Pharmaceuticals, Inc., a corporation organized under the laws of the state of Delaware (the “Issuer”). The address of the principal executive offices of the Issuer is 2130 W. Holcombe Blvd., Ste 800, Houston, Texas 77030. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

**ITEM 2. Identity and Background.**

(a) The Reporting Persons are:

- |    |  |
|----|--|
| 1. | Baker Bros. Advisors LP (the “Adviser”)          |
| 2. | Baker Bros. Advisors (GP) LLC (the “Adviser GP”) |
| 3. | Felix J. Baker                                   |
| 4. | Julian C. Baker                                  |

(b) The business address of each of the Reporting Persons is:

c/o Baker Bros. Advisors LP

667 Madison Avenue, 21<sup>st</sup> Floor

New York, NY 10065

(212) 339-5690

(c) The Adviser is an entity engaged in investment activities, and the Adviser GP is in the business of acting as its general partner and, through the Adviser, investment activities. The principal business of each of Julian C. Baker and Felix J. Baker is to serve as a managing member of the Adviser GP.

(d) and (e) During the past five years, none of the Reporting Persons nor any of the Funds (as defined below) has been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) The Adviser GP is a limited liability company organized under the laws of the State of Delaware. The Adviser is a limited partnership organized under the laws of the State of Delaware. The citizenship of each of Julian C. Baker and Felix J. Baker is the United States of America.

**Item 3. Source and Amount of Funds or Other Consideration**

The disclosure in Item 4 below is incorporated herein by reference. The securities of the Issuer purchased by the Funds (as defined below) reported herein were purchased with working capital both in open market transactions directly with a broker dealer and in private transactions directly with the Issuer. The aggregate purchase price of the securities of the Issuer directly held by the Funds reported herein was approximately \$62,718,963.

**Item 4. Purpose of the Transaction.**

667, L.P. (“667”), Baker Brothers Life Sciences, L.P. (“Life Sciences”) and 14159, L.P. (“14159”, and together with Life Sciences and 667, the “Funds”) hold securities of the Issuer previously purchased in private transactions directly with the Issuer and 667 and Life Sciences hold securities purchased in the open market transactions directly with a broker dealer. All securities were purchased using the working capital of the Funds.

The information in Item 5(c) is incorporated by reference herein.

The Funds hold securities of the Issuer for investment purposes. The Reporting Persons or their affiliates may purchase additional securities or dispose of securities in varying amounts and at varying times depending upon the Reporting Persons' continuing assessments of pertinent factors, including the availability of shares of Common Stock or other securities for purchase at particular price levels, the business prospects of the Issuer, other business investment opportunities, economic conditions, stock market conditions, money market conditions, the attitudes and actions of the board of directors and management of the Issuer, the availability and nature of opportunities to dispose of shares of the Issuer and other plans and requirements of the particular entities. The Reporting Persons may discuss items of mutual interest with the Issuer, which could include items in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

Depending upon their assessments of the above factors, the Reporting Persons or their affiliates may change their present intentions as stated above and they may assess whether to make suggestions to the management of the Issuer regarding financing, and whether to acquire additional securities of the Issuer, including shares of Common Stock (by means of open market purchases, privately negotiated purchases, or otherwise) or to dispose of some or all of the securities of the Issuer, including shares of Common Stock, under their control.

Except as otherwise disclosed herein, at the present time, the Reporting Persons do not have any plans or proposals with respect to any extraordinary corporate transaction involving the Issuer including, without limitation, those matters described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

Item 5. Interest in Securities of the Issuer.

(a) and (b) Items 7 through 11 and 13 of each of the cover pages of this Schedule 13D are incorporated herein by reference. Set forth below is the aggregate number and percentage of shares of Common Stock directly held, as of the date hereof, by each of the following based upon 26,501,110 shares of Common Stock outstanding as of October 30, 2015, as reported in the Issuer's Form 10-Q filed with the SEC on November 9, 2015. Such percentage figures were calculated in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended.

Name	Number of Shares of Common Stock we own or have the right to acquire within 60	Percent of Class Outstanding
------	---	---------------------------------

Edgar Filing: BELLICUM PHARMACEUTICALS, INC - Form SC 13D

	days		
667, L.P.	419,271	1.6	%
Baker Brothers Life Sciences, L.P.	4,375,912	16.5	%
14159, L.P.	70,464	0.3	%
Total	4,865,647	18.4	%

The Adviser GP, Felix J. Baker and Julian C. Baker as principals of the Adviser GP, and the Adviser may be deemed to be beneficial owners of securities of the Issuer directly held by the Funds, and may be deemed to have the power to vote or direct the vote of and the power to dispose or direct the disposition of such securities.

The Reporting Persons disclaim beneficial ownership of the securities of the Issuer held by each of the Funds, and this Schedule 13D shall not be deemed an admission that the Reporting Persons are the beneficial owners of such securities for purposes of Section 13(d) or for any other purpose, except to the extent that any such Reporting Persons actually exercises voting or dispositive power with respect to such securities.

Pursuant to management agreements, as amended, among the Adviser, the Funds, and their respective general partners, the Adviser has complete and unlimited discretion and authority with respect to the Funds' investments and voting power over investments.

(c) The information set forth in Item 4 is hereby incorporated by reference into this Item 5(c). The following transactions in the Issuer's Common Stock were effected by the Funds noted below during the 60 days preceding the filing of this statement using working capital of the applicable purchasing Fund. All purchase transactions were effected in the open market directly with a broker-dealer. Except as disclosed herein, none of the Reporting Persons or their affiliates has effected any other transactions in securities of the Issuer during the past 60 days.

## Edgar Filing: BELLICUM PHARMACEUTICALS, INC - Form SC 13D

Name	Date	Number of Shares	Transaction	Price/Share	Footnote
667, L.P.	11/5/2015	1,400	Purchase	14.7091	1
Baker Brothers Life Sciences, L.P.	11/5/2015	14,540	Purchase	14.7091	1
667, L.P.	11/5/2015	510	Purchase	14.7929	2
Baker Brothers Life Sciences, L.P.	11/5/2015	5,290	Purchase	14.7929	2
667, L.P.	11/5/2015	6,208	Purchase	15.1386	3
Baker Brothers Life Sciences, L.P.	11/5/2015	64,458	Purchase	15.1386	3
667, L.P.	11/6/2015	2,778	Purchase	15.5832	4
Baker Brothers Life Sciences, L.P.	11/6/2015	28,842	Purchase	15.5832	4
667, L.P.	11/9/2015	3,241	Purchase	16.5410	5
Baker Brothers Life Sciences, L.P.	11/9/2015	33,400	Purchase	16.5410	5
667, L.P.	11/10/2015	635	Purchase	18.3846	6
Baker Brothers Life Sciences, L.P.	11/10/2015	6,550	Purchase	18.3846	6
667, L.P.	11/10/2015	4,930	Purchase	19.3908	7
Baker Brothers Life Sciences, L.P.	11/10/2015	50,807	Purchase	19.3908	7
667, L.P.	11/10/2015	9,849	Purchase	19.7988	8
Baker Brothers Life Sciences, L.P.	11/10/2015	101,499	Purchase	19.7988	8
667, L.P.	11/11/2015	11,404	Purchase	19.6434	9
Baker Brothers Life Sciences, L.P.	11/11/2015	117,536	Purchase	19.6434	9
667, L.P.	11/16/2015	3,568	Purchase	20.6447	10
Baker Brothers Life Sciences, L.P.	11/16/2015	36,707	Purchase	20.6447	10
667, L.P.	11/17/2015	278	Purchase	20.6082	11
Baker Brothers Life Sciences, L.P.	11/17/2015	2,857	Purchase	20.6082	11
667, L.P.	11/17/2015	594	Purchase	20.6290	12
Baker Brothers Life Sciences, L.P.	11/17/2015	6,106	Purchase	20.6290	12
667, L.P.	11/18/2015	392	Purchase	20.8313	13
Baker Brothers Life Sciences, L.P.	11/18/2015	4,033	Purchase	20.8313	13
667, L.P.	11/19/2015	571	Purchase	20.8065	14
Baker Brothers Life Sciences, L.P.	11/19/2015	5,878	Purchase	20.8065	14
667, L.P.	11/20/2015	153	Purchase	20.8312	15
Baker Brothers Life Sciences, L.P.	11/20/2015	1,572	Purchase	20.8312	15
667, L.P.	11/23/2015	878	Purchase	22.6389	16
Baker Brothers Life Sciences, L.P.	11/23/2015	9,122	Purchase	22.6389	16
667, L.P.	11/24/2015	878	Purchase	22.2336	17
Baker Brothers Life Sciences, L.P.	11/24/2015	9,122	Purchase	22.2336	17
667, L.P.	11/25/2015	439	Purchase	22.8996	18
Baker Brothers Life Sciences, L.P.	11/25/2015	4,561	Purchase	22.8996	18
667, L.P.	11/30/2015	1,269	Purchase	22.8354	19
Baker Brothers Life Sciences, L.P.	11/30/2015	13,531	Purchase	22.8354	19
667, L.P.	12/1/2015	975	Purchase	22.7398	20
Baker Brothers Life Sciences, L.P.	12/1/2015	10,392	Purchase	22.7398	20
667, L.P.	12/2/2015	2,144	Purchase	23.2154	21
Baker Brothers Life Sciences, L.P.	12/2/2015	22,856	Purchase	23.2154	21
667, L.P.	12/3/2015	1,055	Purchase	22.9832	22
Baker Brothers Life Sciences, L.P.	12/3/2015	11,245	Purchase	22.9832	22
667, L.P.	12/4/2015	5,146	Purchase	22.4850	23
Baker Brothers Life Sciences, L.P.	12/4/2015	54,854	Purchase	22.4850	23





(1) The reported price is a weighted average price. These shares were traded in multiple transactions at a prices ranging from \$14.66 to \$14.88. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the “Staff”), upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(2) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$14.64 to \$14.98. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(3) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$14.91 to \$15.89. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(4) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$15.15 to \$15.98. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(5) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$16.15 to \$16.60. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(6) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$18.30 to \$18.49. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(7) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$19.13 to \$19.70. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(8) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$19.39 to \$20.00. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.



(9) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$19.28 to \$19.80. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(10) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$20.48 to \$20.75. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(11) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$20.55 to \$20.65. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(12) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$20.51 to \$20.70. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(13) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$20.79 to \$20.85. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(14) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$20.72 to \$20.85. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(15) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$20.76 to \$20.85. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(16) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$22.55 to \$22.70. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(17) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$22.16 to \$22.31. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(18) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$22.90 to \$22.90. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(19) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$22.74 to \$22.96. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(20) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$22.52 to \$22.80. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(21) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$23.09 to \$23.25. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(22) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$22.59 to \$23.10. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(23) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from \$22.20 to \$22.75. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the ranges set forth in this footnote.

(d) Certain securities of the Issuer are held directly by 667, a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of Baker Biotech Capital (GP), LLC.

Certain securities of the Issuer are held directly by Life Sciences, a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital, L.P., a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of Baker Brothers Life Sciences Capital (GP), LLC.

Certain securities of the Issuer are held directly by 14159, a limited partnership the sole general partner of which is 14159 Capital, L.P., a limited partnership the sole general partner of which is 14159 Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of 14159 Capital (GP), LLC.

(e) Not applicable.

**ITEM 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information in Item 4 is incorporated by reference herein.

**ITEM 7. Material to Be Filed as Exhibits**

Exhibit	Description
---------	-------------

99.1	Agreement Regarding the Joint Filing of Schedule 13D by and among the Reporting Persons.
------	--



**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: December 24, 2015

**BAKER BROS.  
ADVISORS LP**

By: Baker Bros. Advisors  
(GP) LLC, its general  
partner

By: /s/ Scott L. Lessing  
Name: Scott L. Lessing  
Title: President

**BAKER BROS.  
ADVISORS (GP) LLC**

By: /s/ Scott L. Lessing  
Name: Scott L. Lessing  
Title: President

/s/ Julian C. Baker  
Julian C. Baker

/s/ Felix J. Baker  
Felix J. Baker